Patient-related risk factors appear to be the primary driver of readmissions in hospitals serving a higher proportion of minority patients, according to a study published online yesterday by the journal Surgery. The researchers examined outcomes and patient factors in more than 168,000 colorectal surgery patients treated in 374 California hospitals from 2004-2011, including 47 hospitals with a high percentage of minority patients (63%) compared with the other hospitals (17%). They found that patient factors (such as race, low income and insurance status) accounted for up to 65% of the increased odds for readmission at the minority-serving hospitals, while hospital-level factors (such as procedure volume and type) accounted for up to 40%. The Centers for Medicare & Medicaid Services’ Hospital Readmissions Reduction Program penalizes hospitals for higher-than-expected readmission rates for certain conditions, the authors note. “These findings suggest that CMS should account for patient socio-economic factors when they compare readmission rates,” said Waddah Al-Refaie, M.D., the study’s senior investigator and chief of surgical oncology at MedStar Georgetown University Hospital in Washington, D.C.

Related News Articles

Headline
Hospitals, health systems and other health care organizations can sign up this week to host an intern for this year's Institute for Diversity and Health Equity…
Headline
The Centers for Disease Control and the National Tuberculosis Controllers Association this week released updated recommendations for TB screening and testing…
Headline
The House Ways and Means Committee today held a hearing examining the impact of racial disparities and social determinants of health on maternal mortality.
Headline
The Centers for Medicare…
Headline
The Food and Drug Administration last week alerted health care providers and patients that batteries in certain Medtronic implantable pacemakers and cardiac…
Headline
The Food and Drug Administration Friday issued final guidance clarifying how sponsors may show that a proposed biosimilar product is interchangeable with a…